Colorectal Cancer

A 'watch and wait' surveillance approach may allow certain patients with rectal cancer to achieve excellent outcomes without immediate surgery.

Patients with newly diagnosed metastatic colorectal cancer (mCRC) who had higher levels of vitamin D in their blood lived a median of 8 months longer and experienced greater disease-free survival after their cancer treatment.

Second-line treatment with the VEGFR2 inhibitor ramucirumab (Cyramza) combined with standard FOLFIRI extended survival by 1.6 months versus FOLFIRI alone in patients with metastatic colorectal cancer (mCRC), according to results from the phase III RAISE trial.

Based on a current laboratory research project, Zarah Dulce F. Lucas, MD, discusses microRNAs and their potential to predict brain metastases in patients with triple-negative and HER2-positive breast cancer.

Confusion persists about the best choice of frontline therapy for patients with metastatic colorectal cancer (mCRC) after a landmark clinical trial that was conceived a decade ago to answer that question concluded without a superiority finding

Randall F. Holcombe, MD, professor, Chief Medical Officer, Cancer, Mount Sinai Health System, discusses key takeaways for a practicing oncologist regarding the stool DNA test for colon cancer.

The 5-year survival rate for patients with metastatic colorectal cancer (CRC) remains dismal.

As new therapies enter the treatment landscape for metastatic disease, the role of the oncology nurse becomes even more critical in educating patients about what side effects to look out for and the importance of reporting any adverse events promptly.

Colorectal cancer (CRC) is increasingly being recognized as a heterogeneous disease, with molecular features defining emerging subtypes. Understanding which tests to order in which cases can better direct care for our patients. Increasingly, panel testing has advantages over individual genetic testing.

Nearly two-thirds of patients diagnosed with colorectal cancer report experiencing financial burden during their treatment, according to a study from the University of Michigan.

The FDA has granted a fast track designation to TAS-102 (tipiracil hydrochloride) as a treatment for patients with refractory metastatic colorectal cancer (mCRC), according to an announcement by Taiho Oncology, the company developing the drug in the United States.

All patients with metastatic colorectal cancer should undergo RAS mutation testing to ensure optimal patient selection for EGFR inhibitor therapy.

Alan P. Venook, MD, professor, Department of Medicine (Hematology/Oncology), University of California, San Francisco, discusses the future of colorectal cancer treatment.

The combination of ramucirumab and FOLFIRI significantly improved OS and PFS compared with chemotherapy alone as a second-line treatment for patients with mCRC.

This review highlights that preclinical data and discusses several ongoing clinical trials that are leveraging this information to explore new therapeutic strategies in targeting BRAF-mutated colorectal cancer.

Marc Peeters, MD, PhD, department of oncology, Antwerp University Hospital, Antwerpen, Belgium, discusses the efficacy and safety of panitumumab versus cetuximab as seen in the ASPECCT trial in colorectal cancer (CRC).

Alan P. Venook, MD, professor, Department of Medicine (Hematology/Oncology), University of California, San Francisco, discusses implications from the CALGB/SWOG 80405 trial of targeted therapies administered in colorectal cancer.

The FDA has approved the noninvasive stool-based DNA test Cologuard for the detection of colorectal cancer or cancer precursors in asymptomatic patients at average risk.